GPT and metabolic dysfunction-associated steatotic liver disease: In NAFLD, the TZDs have been shown to reduce serum ALT levels and hepatic steatosis, with some effects on necroinflammation activity, but effects on hepatic fibrosis have not usually been observed; this could relate to short duration of use, typically 6–12 months [106–109].